Loading…
← CockpitCompetitor Analysis › SRTA Strata Critical Medical, Inc. Class AOpen in the cockpit ↗

Strata Critical Medical, Inc. Class ASRTACompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Momentum neutral 41
Mkt cap
$443M
US dollars, full cap
Free float
76%
of shares outstanding
$/day
$6.47M
20-day average traded
Fwd P/E
86.3×
forward earnings
ROIC−WACC
-21.7 pp
WACC 17.8%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$4.96
1D-5.3%
1W-17.5%
1M+5.8%
3M-16.8%
6M-10.5%
YTD+3.1%
1Y+11.5%
ATR %6.0%
Beta1.90
52w lowhigh23.7% off high

What Strata Critical Medical does

Employees: 601

Strata Critical Medical at a glance

Size Strata Critical Medical (SRTA) is a United States Health Care company (Medical/Nursing Services) with a market value of $443M, the 2760th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.96 on 18 Nov 2026.

Performance Over six months the shares fell 10.5%, against -3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 22.7% over the last twelve months (peer median +5.1%); the operating margin is -4.2% (peer median 8.4%).

Valuation It trades at 86.3× forward earnings against a peer median of 16.9× (most expensive of 13).

Capital Return on invested capital runs 21.7 points below its cost of capital (17.8% WACC).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 98SRTA 86
Six months, rebased to 100: Strata Critical Medical against the median of its 20 peers (local-currency closes).

Strata Critical Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$281M$197M$147M$225M$146M
Revenue growth—+34%-35%+54%—
Gross profit$42.7M$38.3M$28.0M$36.1M$17.4M
EBITDA$10.2M-$2.91M-$15.3M-$61.0M-$44.8M
Net income-$21.0M-$15.6M-$27.3M-$56.1M-$27.3M
Free cash flow-$737,000-$59.9M-$35.5M-$34.5M-$37.9M
Capital expenditure$11.1M$11.0M$33.0M$2.11M$730,000
Total debt$3.62M$3.31M$3.02M$24.5M$18.3M

Quarterly statements and history in the cockpit →

Strata Critical Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%127120ACLIDXJSLL9860301060M12DNAAYUPA300642NIOXAUNAWELLDRAGARWQFLGTNEPHROPLUSGMRSSRTA6-month return →1-month return →
Up and to the right = strong over both horizons. Strata Critical Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×ACLIDXJSLL9860M12NIOXAUNA3218WELLNEPHROPLUSGMRSSRTARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Strata Critical Medical is the large dot.

Strata Critical Medical competitors and peer comparison

How Strata Critical Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Strata Critical Medical against its 20 peers (data as of 18 Nov 2026)
MeasureSRTAPeer medianRank in peer set
1-month return+5.8%-9.6%6th highest of 21
6-month return-10.5%-3.5%6th lowest of 20
Distance from 52-week high-23.7%-30.8%8th highest of 21
Revenue growth (TTM)+22.7%+5.1%7th highest of 21
Operating margin-4.2%8.4%4th lowest of 21
Forward P/E86.3×16.9×most expensive of 13
ROIC minus cost of capital-21.7 pp-0.3 pp4th lowest of 20
Net debt / EBITDA-3.8×1.6×least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are Strata Critical Medical's closest peers?
The cockpit's peer set: JS Link (127120.KS), Australian Clinical Labs (ACL.AX), Integral Diagnostics (IDX.AX), Jeena Sikho Lifecare (JSLL.NS), ADICON (9860.HK), Shanghai Labway Clinical Laboratory (301060.SZ), M1 Kliniken (M12.DE), Ginkgo Bioworks (DNA).
Is Strata Critical Medical expensive compared with its peers?
On forward p/e it trades at 86.3× against a peer median of 16.9×, most expensive of 13 in its peer set.
How has Strata Critical Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -10.5% against -3.5% for the median peer; over one year +11.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.